Phase II Study Evaluating the Safety and Efficacy of GSK315234A in Patients With Rheumatoid Arthritis

A Randomized, Double-blind, Placebo-controlled, Bayesian Adaptive Dose Finding Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Intravenous Infusions GSK315234A in Patients With Active Rheumatoid Arthritis (RA)

This is a randomized, double-blinded, placebo-controlled adaptive, dose finding study to investigate the safety, tolerability, PK, PD and efficacy of single and repeat intravenous infusions of GSK315243A in patients with active rheumatoid arthritis. The study is divided into 2 parts: Part A is an adaptive, dose finding phase which will provide safety, tolerability, PK and PD on single intravenous infusions. Part B is a repeat dose phase which will provide safety, tolerability, PK, PD and efficacy following repeat intravenous infusions of a selected dose level.

Study Overview

• Status: Completed
• Conditions: Arthritis, Rheumatoid
• Intervention / Treatment: Drug: Placebo; Drug: GSK3152314A

• Study Type: Interventional
• Enrollment (Actual): 135
• Phase: Phase 2

Contacts and Locations

Study Locations

• Australia
  • Queensland
    • Woolloongabba, Queensland, Australia, 4102
      • GSK Investigational Site
  • Victoria
    • Heidelberg, Victoria, Australia, 3084
      • GSK Investigational Site
    • Melbourne, Victoria, Australia, VIC 30004
      • GSK Investigational Site
• New Zealand
  • Christchurch, New Zealand, 8011
    • GSK Investigational Site
  • Hamilton, New Zealand, 2001
    • GSK Investigational Site
  • Wellington, New Zealand, 6035
    • GSK Investigational Site
• Russian Federation
  • Moscow, Russian Federation, 115522
    • GSK Investigational Site
  • Moscow, Russian Federation, 129327
    • GSK Investigational Site
  • Novosibirsk, Russian Federation, 630117
    • GSK Investigational Site
  • Smolensk, Russian Federation, 214018
    • GSK Investigational Site
  • Yaroslavl, Russian Federation, 150062
    • GSK Investigational Site
• Serbia
  • Belgrade, Serbia, 11000
    • GSK Investigational Site
  • Belgrade, Serbia, 11080
    • GSK Investigational Site
  • Niska Banja, Serbia, 18205
    • GSK Investigational Site
• Ukraine
  • Donetsk, Ukraine, 83114
    • GSK Investigational Site
  • Kyiv, Ukraine, 03680
    • GSK Investigational Site
  • Kyiv, Ukraine, 03103
    • GSK Investigational Site
  • Lviv, Ukraine, 79013
    • GSK Investigational Site
  • Zaporizhzhya, Ukraine, 69035
    • GSK Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Males or females between 18 and 75 years of age, inclusive.
• All subjects must use acceptable contraception (as defined in the study restriction section) to ensure that no pregnancies occur during the course of the study and for at least 12 weeks after dosing for males and for 32 weeks after dosing for females (see Section 7.1 on contraception for more details).
• Body mass index within the range 18.5 - 35 kg/m2 inclusive, in addition to a weight range of 55 - 95kg.
• The subject must be capable of giving informed consent and can comply with the study requirements and timetable.
• The subject must have a diagnosis of RA according to the revised 1987 criteria of the American College of Rheumatology (ACR) (see Appendix 2).
• The subject must have a DAS28 disease activity score of greater than 4.2 at screening and pre-dose.
• The subject must have a CRP serum level of >/0.5mg/dl or an ESR level 28mm/hour at screening and pre-dose
• The subject has NOT received any biological therapy in the past, including biologicals for the treatment of rheumatoid arthritis
• The subject must have liver function tests including alanine transaminase (ALT) and aspartate transaminase (AST) within 1.5 times the upper limit of normal (ULN) and alkaline phosphatase (ALP) within 3 times ULN at screening. The patient must also have total bilirubin within the ULN at screening.
• The subject must have received at least 3 months of methotrexate and must be on a stable dose of methotrexate (up to 25 mg/week) for at least 8 weeks prior to screening and be willing to remain on this dose throughout the study.
• If sulfasalazine is being taken in addition to methotrexate, the subject must be on a stable dose for at least 4 weeks prior to screening and be willing to remain on this dose throughout the study.
• If hydroxychloroquine or chloroquine is being taken in addition to methotrexate, the subject must be on a stable dose for at least 3 months prior to screening and be willing to remain on this dose throughout the study.
• Those subjects on other oral anti-rheumatic therapies, which may include Non Steroidal Anti Inflammatory Drugs (NSAIDs), COX-2 inhibitors, oral glucocorticoids e.g. prednisolone (£10mg/day) must be on stable dosing regimens for at least 4 weeks prior to screening and be willing to remain on this regime throughout the study. Subjects receiving intramuscular glucocorticoids e.g methylprednisolone (£120 mg/month) must be on a stable dosing regimen for at least 3 months prior to screening and be willing to remain on this regimen throughout the study.
• The subject must be on a stable dose of folate supplements (5 mg/week) for at least 4 weeks prior to do

Exclusion Criteria:

• Any clinically relevant abnormality identified on the screening medical assessment, laboratory examination (e.g. haematology parameter outside the normal limits), or ECG (12 Lead or Holter).
• The subject has a positive Hepatitis B surface antigen or Hepatitis C antibody result at screening.
• The subject has a history of elevated liver function tests on more than one occasion (ALT, AST and ALP > 3 x Upper Limit of Normal (ULN); total bilirubin > 1.5 x ULN) in the past 6 months.
• Previous exposure or past infection caused by Mycobacterium tuberculosis
• The subject has an acute infection.
• The subject has a history of repeated, chronic or opportunistic infections that, in the opinion of the investigator and/or GSK medical monitor, places the subject at an unacceptable risk as a participant in this trial.
• The subject has a history of malignancy, except for surgically cured basal cell carcinoma or females with cured cervical carcinoma (> 2 yrs prior).
• The subject has a history of human immunodeficiency virus (HIV) or other immunodeficiency disease.
• The subject whose calculated creatinine clearance is less than 50ml/min
• The subject has significant cardiac, pulmonary, metabolic, renal, hepatic or gastrointestinal conditions that, in the opinion of the investigator and/or GSK medical monitor, places the subject at an unacceptable risk as a participant in this trial.
• The subject has taken cyclosporine, leflonomide, cyclophosphamide or azathioprine within 1 month of screening. Subjects that have taken cyclosporine, leflonomide, cyclophosphamide or azathioprine in the past must have recovered from all drug related adverse events.
• The subject has taken gold salts or d-penicillamine within 1 month prior to screening. Subjects that have taken gold salts or d-penicillamine in the past must have recovered from all drug related adverse events.
• The subject has received intra-articular glucocorticoids within 1 month of screening.
• Recent history of bleeding disorders, anaemia, peptic ulcer disease, haematemesis or gastrointestinal bleeding
• Subjects with a history of haematological disease or acquired platelet disorders, including drug-induced thrombocytopaenia, acute idiopathic thrombocytopaenia or von Willebrand's disease.
• Subjects with a known risk of intra-cranial haemorrhage including Central Nervous System (CNS) surgery within the last 12 months, arterial vascular malformations, aneurysms, significant closed head trauma within 6 months or any other incident the investigator and/or medical monitor considers to be relevant.
• The subject has Hb <10 g/deciliter (dL) and platelet count < 150 x 109/Liter (L)
• Donation of blood in excess of 500 ml within a 56 day period prior to dosing
• An unwillingness of male subjects to abstain from sexual intercourse with pregnant or lactating women; or an unwillingness of the male subject to use a condom with spermicide in addition to having their female partner use another form of contraception such as an interuterine device (IUD), diaphragm with spermicide, oral contraceptives, injectable progesterone, subdermal implants of levonorgestrel or a tubal ligation if the woman could become pregnant for at least 12 weeks after dosing
• An unwillingness of female subject of child bearing potential to use adequate contraception, as defined in the study restriction section. If necessary, women of non-child bearing potential (i.e. post-menopausal or surgically sterile e.g. tubal ligation or hysterectomy or bilateral oophorectomy) will be confirmed. Postmenopausal status will be confirmed by serum follicle stimulating hormone (FSH) and oestradiol concentrations at screening. Surgical sterility will be defined as females who have had a documented hysterectomy, tubal ligation or bilateral oophorectomy.
• The subject has a history of use of drugs of abuse within 12 months prior to screening.
• History of regular alcohol consumption exceeding average weekly intake of greater than 21 units or an average daily intake of greater than 3 units (males) or an average weekly intake of greater than 14 units or an average daily intake of greater than 2 units (females). Subjects who regularly consume more than 12 units of alcohol in a 24h period will also be excluded. 1 unit is equivalent to a half-pint (220ml) of beer/lager or 1 (25ml) measure of spirits or 1 glass (125ml) of wine.
• Positive pregnancy test or lactating at screening.
• Participation in a trial with any investigational drug within 3 months or 5 half-lives (whichever is longer) before

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo; matching placebo	Drug: Placebo; matching placebo
Active Comparator: GSK315234A; Part A single IV dose; Part B 3 repeat IV dose at Day 1, Day 28 and Day 56; Part C single SC dose	Drug: GSK3152314A; Part A single IV dose; Part B 3 repeat IV dose at Day 1, Day 28 and Day 56; Part C single SC dose

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
• To assess the safety and tolerability of GSK315234A after single and repeat intravenous infusions in subjects with active rheumatoid arthritis on a background of methotrexate.	safety assessment includes AEs, vital signs, ECG, clinical laboratory tests.	Part A total of 150Days; Part B total of 236 days and Part C total of 180 days
• To assess the effect of GSK315234A on disease activity [as defined by Disease Activity Score (DAS) 28 score] on Day 28 after a single intravenous infusion	DAS28 at Day 28 and DAS28 at Day 56	Part A total of 150 days
• To assess the effect of GSK315234A on disease activity [as defined by Disease Activity Score (DAS) 28 score] on Day 56 in subjects with active rheumatoid arthritis on a background of methotrexate (Part B and Part C).	DAS28 scores on Day 56 (Part B and C)	Part B total of 236 days and Part C total of 180 days

Secondary Outcome Measures

Outcome Measure	Time Frame
Weighted mean DAS28 after single and repeat intravenous doses	Part A total of 150Days; Part B total of 236 days and Part C total of 180 days
Plasma PK parameters of GSK315234A after single and repeat intravenous doses including free, and bound GSK315234A (serum) concentrations, AUC(0-¥), Cmax, clearance, volume of distribution and accumulation ratio	Part A total of 150Days; Part B total of 236 days and Part C total of 180 days
DAS28 and EULAR response criteria after single and repeat intravenous doses	Part A total of 150Days; Part B total of 236 days and Part C total of 180 days
ACR20/ACR50/ACR70 response after single and repeat intravenous doses	Part A total of 150Days; Part B total of 236 days and Part C total of 180 days
Number of swollen joints assessed using 28-joint counts.	Part A total of 150Days; Part B total of 236 days and Part C total of 180 days
Number of tender/painful joints assessed using 28-joint counts.	Part A total of 150Days; Part B total of 236 days and Part C total of 180 days
Subject's pain assessment	Part A total of 150Days; Part B total of 236 days and Part C total of 180 days
Physician's global assessment of arthritis condition.	Part A total of 150Days; Part B total of 236 days and Part C total of 180 days
Patients' global assessment of arthritis condition.	Part A total of 150Days; Part B total of 236 days and Part C total of 180 days
Functional disability index (Health Assessment Questionnaire)	Part A total of 150Days; Part B total of 236 days and Part C total of 180 days
C-reactive Protein (CRP).	Part A total of 150Days; Part B total of 236 days and Part C total of 180 days
ESR	Part A total of 150Days; Part B total of 236 days and Part C total of 180 days
Global Fatigue Index	Part A total of 150Days; Part B total of 236 days and Part C total of 180 days
HAQ disability index	Part A total of 150Days; Part B total of 236 days and Part C total of 180 days
Pharmacodynamic biomarkers after single and repeat intravenous doses:	Part A total of 150Days; Part B total of 236 days and Part C total of 180 days
Characteristic AUC50 and EC50 for clinical endpoint changes with plasma exposure model, as assessed by sigmoid Emax and indirect response PK/PD models.	Part A total of 150Days; Part B total of 236 days and Part C total of 180 days
Immunogenicity (Human anti-GSK315234A antibodies)	Part A total of 150Days; Part B total of 236 days and Part C total of 180 days
• To assess the relative bioavailability of GSK315234A administered subcutaneously (Part C) as compared to intravenous administration in subjects with active rheumatoid arthritis on a background of methotrexate	Part C total of 180days

Collaborators and Investigators

• Sponsor: GlaxoSmithKline

Publications and helpful links

General Publications

• Choy EH, Bendit M, McAleer D, Liu F, Feeney M, Brett S, Zamuner S, Campanile A, Toso J. Safety, tolerability, pharmacokinetics and pharmacodynamics of an anti- oncostatin M monoclonal antibody in rheumatoid arthritis: results from phase II randomized, placebo-controlled trials. Arthritis Res Ther. 2013 Sep 24;15(5):R132. doi: 10.1186/ar4312.

Helpful Links

• Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.

Study record dates

Study Major Dates

• Study Start: April 1, 2008
• Primary Completion (Actual): December 1, 2010
• Study Completion (Actual): December 1, 2010

Study Registration Dates

• First Submitted: April 22, 2008
• First Submitted That Met QC Criteria: May 7, 2008
• First Posted (Estimate): May 8, 2008

Study Record Updates

• Last Update Posted (Estimate): December 1, 2016
• Last Update Submitted That Met QC Criteria: November 30, 2016
• Last Verified: November 1, 2016

More Information

Terms related to this study

• Keywords: monoclonal antibody; adaptive study,; DAS28,; GSK315234A;; rheumatoid arthritis,
• Additional Relevant MeSH Terms: Immune System Diseases; Autoimmune Diseases; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Arthritis; Arthritis, Rheumatoid
• Other Study ID Numbers: 104972

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Yes
• IPD Plan Description: Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

Study Data/Documents

1. Dataset Specification
   Information identifier: 104972
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
2. Study Protocol
   Information identifier: 104972
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
3. Annotated Case Report Form
   Information identifier: 104972
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
4. Informed Consent Form
   Information identifier: 104972
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
5. Clinical Study Report
   Information identifier: 104972
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
6. Statistical Analysis Plan
   Information identifier: 104972
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
7. Individual Participant Data Set
   Information identifier: 104972
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register